These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 31719099)

  • 21. Next generation sequencing is informing phenotype: a TP53 example.
    O'Shea R; Clarke R; Berkley E; Giffney C; Farrell M; O'Donovan E; Gallagher DJ
    Fam Cancer; 2018 Jan; 17(1):123-128. PubMed ID: 28509937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer Risks Associated With
    Fortuno C; Feng BJ; Carroll C; Innella G; Kohlmann W; Lázaro C; Brunet J; Feliubadaló L; Iglesias S; Menéndez M; Teulé A; Ballinger ML; Thomas DM; Campbell A; Field M; Harris M; Kirk J; Pachter N; Poplawski N; Susman R; Tucker K; Wallis M; Williams R; Cops E; Goldgar D; ; James PA; Spurdle AB
    JCO Precis Oncol; 2024 Feb; 8():e2300453. PubMed ID: 38412388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and molecular characterization of patients fulfilling Chompret criteria for Li-Fraumeni syndrome in Southern Brazil.
    Matzenbacher Bittar C; de Araújo Rocha YM; Vieira IA; Rosset C; Andreis TF; Sartor ITS; Artigalás O; Netto CBO; Alemar B; Macedo GS; Ashton-Prolla P
    PLoS One; 2021; 16(9):e0251639. PubMed ID: 34529667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel TP53 germline inframe deletion identified in a Spanish series of Li-fraumeni syndrome suspected families.
    Llovet P; Illana FJ; Martín-Morales L; de la Hoya M; Garre P; Ibañez-Royo MD; Pérez-Segura P; Caldés T; García-Barberán V
    Fam Cancer; 2017 Oct; 16(4):567-575. PubMed ID: 28573494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study.
    Villani A; Tabori U; Schiffman J; Shlien A; Beyene J; Druker H; Novokmet A; Finlay J; Malkin D
    Lancet Oncol; 2011 Jun; 12(6):559-67. PubMed ID: 21601526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A case of late-onset Li-Fraumeni-like syndrome with unilateral breast cancer.
    Cho Y; Kim J; Kim Y; Jeong J; Lee KA
    Ann Lab Med; 2013 May; 33(3):212-6. PubMed ID: 23667851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based Testing.
    Rana HQ; Gelman R; LaDuca H; McFarland R; Dalton E; Thompson J; Speare V; Dolinsky JS; Chao EC; Garber JE
    J Natl Cancer Inst; 2018 Aug; 110(8):863-870. PubMed ID: 29529297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prenatal diagnosis in Li-Fraumeni syndrome.
    Avigad S; Peleg D; Barel D; Benyaminy H; Ben-Baruch N; Taub E; Shohat M; Goshen Y; Cohen IJ; Yaniv I; Zaizov R
    J Pediatr Hematol Oncol; 2004 Sep; 26(9):541-5. PubMed ID: 15342977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
    Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
    Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parent decision-making around the genetic testing of children for germline TP53 mutations.
    Alderfer MA; Zelley K; Lindell RB; Novokmet A; Mai PL; Garber JE; Nathan D; Scollon S; Chun NM; Patenaude AF; Ford JM; Plon SE; Schiffman JD; Diller LR; Savage SA; Malkin D; Ford CA; Nichols KE
    Cancer; 2015 Jan; 121(2):286-93. PubMed ID: 25223899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transmission of a
    Cotter JA; Szymanski L; Karimov C; Boghossian L; Margol A; Dhall G; Tamrazi B; Varaprasathan GI; Parham DM; Judkins AR; Biegel JA
    Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29581140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort.
    Bakhuizen JJ; Hogervorst FB; Velthuizen ME; Ruijs MW; van Engelen K; van Os TA; Gille JJ; Collée M; van den Ouweland AM; van Asperen CJ; Kets CM; Mensenkamp AR; Leter EM; Blok MJ; de Jong MM; Ausems MG
    Fam Cancer; 2019 Apr; 18(2):273-280. PubMed ID: 30607672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriers.
    Macedo GS; Vieira IA; Vianna FSL; Alemar B; Giacomazzi J; Brandalize APC; Caleffi M; Volc SM; de Campos Reis Galvão H; Palmero EI; Achatz MI; Ashton-Prolla P
    Fam Cancer; 2018 Apr; 17(2):269-274. PubMed ID: 28756477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two TP53 germline mutations in a classical Li-Fraumeni syndrome family.
    van Hest LP; Ruijs MW; Wagner A; van der Meer CA; Verhoef S; van't Veer LJ; Meijers-Heijboer H
    Fam Cancer; 2007; 6(3):311-6. PubMed ID: 17318340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome.
    Birch JM; Blair V; Kelsey AM; Evans DG; Harris M; Tricker KJ; Varley JM
    Oncogene; 1998 Sep; 17(9):1061-8. PubMed ID: 9764816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium.
    Mai PL; Malkin D; Garber JE; Schiffman JD; Weitzel JN; Strong LC; Wyss O; Locke L; Means V; Achatz MI; Hainaut P; Frebourg T; Evans DG; Bleiker E; Patenaude A; Schneider K; Wilfond B; Peters JA; Hwang PM; Ford J; Tabori U; Ognjanovic S; Dennis PA; Wentzensen IM; Greene MH; Fraumeni JF; Savage SA
    Cancer Genet; 2012 Oct; 205(10):479-87. PubMed ID: 22939227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Rare
    Powers J; Pinto EM; Barnoud T; Leung JC; Martynyuk T; Kossenkov AV; Philips AH; Desai H; Hausler R; Kelly G; Le AN; Li MM; MacFarland SP; Pyle LC; Zelley K; Nathanson KL; Domchek SM; Slavin TP; Weitzel JN; Stopfer JE; Garber JE; Joseph V; Offit K; Dolinsky JS; Gutierrez S; McGoldrick K; Couch FJ; Levin B; Edelman MC; Levy CF; Spunt SL; Kriwacki RW; Zambetti GP; Ribeiro RC; Murphy ME; Maxwell KN
    Cancer Res; 2020 Sep; 80(17):3732-3744. PubMed ID: 32675277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Whole-genome sequencing analysis of phenotypic heterogeneity and anticipation in Li-Fraumeni cancer predisposition syndrome.
    Ariffin H; Hainaut P; Puzio-Kuter A; Choong SS; Chan AS; Tolkunov D; Rajagopal G; Kang W; Lim LL; Krishnan S; Chen KS; Achatz MI; Karsa M; Shamsani J; Levine AJ; Chan CS
    Proc Natl Acad Sci U S A; 2014 Oct; 111(43):15497-501. PubMed ID: 25313051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations.
    Ponti F; Corsini S; Gnoli M; Pedrini E; Mordenti M; Sangiorgi L
    Fam Cancer; 2016 Oct; 15(4):635-43. PubMed ID: 26956143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Higher-than-expected population prevalence of potentially pathogenic germline TP53 variants in individuals unselected for cancer history.
    de Andrade KC; Mirabello L; Stewart DR; Karlins E; Koster R; Wang M; Gapstur SM; Gaudet MM; Freedman ND; Landi MT; Lemonnier N; Hainaut P; Savage SA; Achatz MI
    Hum Mutat; 2017 Dec; 38(12):1723-1730. PubMed ID: 28861920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.